Free · No account required · Powered by AI across the world's largest grants + funders database
Currently focused on US federal, state, and foundation grants.
The purpose of this Notice of Funding Opportunity (NOFO) is to solicit competitive revision (formerly known as competitive supplement) applications from awardees with active U19 awards funded under RFA-RM-22-015 as part ofthe NIH Somatic Cell Genome Editing program, in order to expand the scope of the original award to allow first in human genome editing clinical trials using the therapeutic clinical candidates developed through the U19 award. RFA-RM-22-015 did not allow a clinical trial, whereas the present NOFO (RFA-RM-24-008) requires a clinical trial.
Funding Opportunity Number: RFA-RM-24-008. Assistance Listing: 93.310. Funding Instrument: CA. Category: HL.
Based on current listing details, eligibility includes: Eligible applicants: Independent school districts; Native American tribal governments (Federally recognized); Public housing authorities / Indian housing authorities; Others (see text field entitled Additional Information on Eligibility for clarification). Other Eligible Applicants include the following: Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Organization) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. Applicants should confirm final requirements in the official notice before submission.
Current published award information indicates Funding amounts vary based on project scope and sponsor guidance. Always verify allowable costs, matching requirements, and funding caps directly in the sponsor documentation.
The current target date is February 13, 2026. Build your timeline backwards from this date to cover registrations, approvals, attachments, and final submission checks.
To support secondary analysis of AnVIL datasets and increase utilization of the AnVIL platform for small research projects by eliminating the cost barriers new users face. Through this additional analysis, this RFA will illuminate the value of NHGRI datasets for secondary research and the effectiveness of AnVIL to stimulate further discovery. Funding Opportunity Number: RFA-HG-25-005. Assistance Listing: 93.172. Funding Instrument: G. Category: HL. Award Amount: Up to $125K per award.
The goal of this Notice of Funding Opportunity (NOFO) is to accelerate the establishment ofeffective and reliable biomarkers of Alzheimers disease (AD) and AD-related dementias (ADRD) for usein therapy/medical product discovery and development, clinical trials and/or clinical practice. Specifically, this NOFO willsupport analytical and/or clinical validationof a biomarker, composite biomarker or biomarker signature, withrigor comparable with the expectations described in the Food and Drug Administration (FDA)Biomarker Qualification Program (BQP) or recommended by other FDA regulatory pathways. Funding Opportunity Number: PAR-25-209. Assistance Listing: 93.866. Funding Instrument: CA. Category: HL.
This is a Notice of Funding Opportunity (NOFO) for a Single Source that invites a recipient organization funded under the Electronic Medical Records and Genomics (eMERGE): Genomic Risk Assessment and Management Network Coordinating Center (RFA-HG-19-015) to participate in the Outcomes of Electronic Medical Records and Genomics (eMERGE) Genomic Risk Assessment and Management Network. Please see Section III. Eligibility for additional information. In accordance with NIH standard peer-review processes, the application will be peer-reviewed, and only meritorious applications will be considered.The NHGRI is announcing its intent to issue a single source cooperative agreement award to Vanderbilt University Medical Center to continue coordination of the eMERGE Risk Assessment Network. The eMERGE Network will extend through April 2030 follow-up and collection of outcome data on the roughly 25,000 patients receiving genomically informed risk assessment (GIRA) and management recommendations. Funding Opportunity Number: RFA-HG-26-008. Assistance Listing: 93.172. Funding Instrument: CA. Category: HL. Award Amount: Up to $687K per award.
